Skip to main content

Table 1 Characteristics of 226 patients and 15 controls vaccinated against seasonal influenza 2015–2016

From: Response to influenza vaccination in immunocompromised children with rheumatic disease: a prospective cohort study

Characteristics All patients
(n = 226)
bDMARDs monotherapya
(n = 80)
bDMARDs
+ DMARDs b
(n = 110)
Rituximabc
(n = 5)
Systemic disordersd
(n = 18)
Othere
(n = 13)
Controls
(n = 15)
Age, years 14.2 (10.8–17.1) 14.1 (10.1–17.2) 13.7 (11.2–16.7) 15.3 (14.6–16.4) 15.9 (12.3–16.9) 17.2 (14.5–18.4) 12.2 (11.0-15.5)
Male sex 78 (34.5) 30 (37.5) 36 (32.7) 0 6 (33.3) 6 (46.2) 9 (60.0)
Age at onset of symptoms 7.8 (3.2–11.0) 7.1 (2.9–9.5) 7.0 (2.8–11.0) 11.3 (10.1–12.5) 11.0 (8.8–14.3) 9.6 (6.3–11.5) -
Age at diagnosis 9.5 (4.4–12.8) 8.0 (3.4–11.9) 9.5 (5.3–12.7) 12.8 (10.1–13.4) 11.9 (10.0-14.8) 10.3 (7.8–12.2) -
JIA – ILAR criteria
 Systemic arthritis 7 3 2    2  
 Oligoarthritis 67 35 31    1  
 Polyarthritis (RF-negative) 81 27 50 1   3  
 Polyarthritis (RF-positive) 5 1 4     
 Psoriatic arthritis 14 3 10    1  
 Enthesitis-related arthritis 11 4 6    1  
Undifferentiated arthritis
Systemic connective tissue disorders
 Granulomatosis with polyangiitis 4    1 3   
 Juvenile dermatomyositis 4     4   
 Mixed connective tissue disease 4     4   
 Polymyositis 2     2   
 Scleroderma 3     3   
 Sjogren syndrome 1    1    
 Systemic lupus erythematosus 3    2 1   
 Other mixed connective tissue syndrome 1     1   
Other
 Behchet’s disease 1   1     
 Chronic recurrent multifocal osteomyelitis 11 7 3    1  
 Familial Mediterranean fever 4   1    3  
 Iridocyclitis 2   1    1  
 Sarcoidosis 1   1     
Duration of bDMARDs therapy, years 1.1 (0.4-2.0) 1.3 (0.3–2.3) 0.9 (0.4–1.8)    0.5 (0-0.7)  
Duration from last bDMARDs injection to vaccination, days 5.0 (2.0-11.5) 5.0 (2.0–9.0) 5.0 (3.0–14.0)    5.5 (0.0–10.0)  
  1. Data are median (interquartile range) or No. (%)
  2. Abbreviations: DMARDs disease modifying antirheumatic drugs. bDMARDs biological DMARDs. ILAR International League of Associations for Rheumatology. JIA Juvenile idiopathic arthritis. RF Rheumatoid factor
  3. a bDMARDs used: TNFα inhibitors 87.5 %, costimulation modulator (inhibits T lymphocyte)1,25 %, IL-6 inhibitor 11.25 %
  4. b bDMARDs used: TNFα inhibitors 87.4 %, costimulation modulator (inhibits T lymphocyte) 4.5 %, IL-1 inhibitor 0.9 %, IL-6 inhibitor 8.1 %. DMARDS used: Methotrexate 94.5 %, leflunomide 3.6 %, mycophenolate mofetil 0.9 %, colchicine 0.9 %, methotrexate + colchicine 0.9 %
  5. c Medication in addition to rituximab: glucocorticoid + immunoglobulin + mycophenolate mofetil 20 %, glucocorticoid + hydroxychloroquine + mycophenolate mofetil 40 %, glucocorticoid + hydroxychloroquine + mycophenolate mofetil + glucocorticoid bolus 20 %, leflunomide 20 %
  6. d Medication: glucocorticoid + mycophenolate mofetil + hydroxychloroquine 27.8 %, glucocorticoid + mycophenolate mofetil 11.1 %, glucocorticoid + immunoglobulin + methotrexate 5.6 %, mycophenolate mofetil 16.7 %, methotrexate 27.8 %, hydroxychloroquine 5.6 %, no medication 5.6 %
  7. e Medication: glucocorticoid bolus + TNFα inhibitor + glucocorticoid + methotrexate 7.7 %, glucocorticoid bolus + IL-6 inhibitor + glucocorticoid + methotrexate 7.7 %, glucocorticoid bolus + TNFα inhibitor + methotrexate 7.7 %, glucocorticoid bolus + TNFα inhibitor + mycophenolate mofetil 7.7 %, TNFα inhibitor + glucocorticoid + methotrexate 15.4 %, IL-6 inhibitor + glucocorticoid + methotrexate 7.7 %, IL-1 inhibitor + glucocorticoid 7.7 %, TNFα inhibitor + glucocorticoid + mycophenolate mofetil 7.7 %, glucocorticoid + leflunomide 7.7 %, no medication 23.1 %
\